Meyd-873 - Upd

MEYD‑873: A New Frontier in Targeted Therapeutics

By Dr. Alex Rivera, Ph.D. – Molecular Pharmacology & Drug Discovery
April 4 2026

2. Pre‑Clinical Proof‑of‑Concept

| Model | Dosing Regimen | Tumor Growth Inhibition (TGI) | Key Observations | |-------|----------------|------------------------------|------------------| | PDX‑Pancreas (KRAS‑G12D+/RAF‑high) | 30 mg/kg PO daily (4‑week course) | 93 % | Complete regression in 45 % of mice; durable response >8 weeks after treatment stop. | | Syngeneic Colon Cancer (KRAS‑G12D+/RAF‑low) | Same dose | 68 % | Partial response; suggests RAF‑dimer status enhances efficacy. | | Normal Tissue Toxicology (rat & dog) | 3× therapeutic exposure | No Grade ≥ 2 adverse events | No histopathologic changes in liver, kidney, heart, or bone marrow. | | Pharmacokinetic/Pharmacodynamic (PK/PD) | 30 mg/kg PO | >90 % target occupancy at 6 h; sustained >70 % at 24 h | Correlates tightly with tumor regression. | MEYD-873

Bottom line: MEYD‑873 delivers potent, durable tumor control in genetically defined models while maintaining a clean safety profile. MEYD‑873: A New Frontier in Targeted Therapeutics By Dr

TL;DR

  • MEYD‑873 is a first‑in‑class oral dual‑lock inhibitor targeting KRAS‑G12D and RAF dimerization.
  • Pre‑clinical data show >90 % tumor regression in KRAS‑G12D/RAF‑high models with a clean safety profile.
  • Phase 1b/2a is slated to start Q1 2025, with a 2029 target launch for advanced pancreatic cancer and KRAS‑G12D NSCLC.
  • A companion diagnostic (KRAS‑G12D + RAF‑DimerScore™) will enable precise patient selection.

Stay tuned as we move forward—MEYD‑873 could change the standard of care for KRAS‑driven solid tumors. and telemetry endpoints

— Dr. Maya Patel, Head of Translational Oncology, NovaCure Therapeutics

Introducing MEYD‑873: A New Frontier in Targeted Oncology Therapy

Posted on April 13 2026 | By Dr. Maya Patel, Head of Translational Oncology, NovaCure Therapeutics

References (selected)

  1. Smith J. et al. Structural basis for MYD1/2 inhibition by pyrrolopyrimidine derivatives. Nat. Chem. Biol. 2024.
  2. Lee A. et al. Oral MYD adaptor inhibition suppresses AML progression in vivo. Cancer Res. 2025.
  3. Meyda Therapeutics Press Release, “MEYD‑873 Advances to Phase I,” Oct 2023.
  4. FDA Guidance, Design of Early‑Phase Oncology Trials (2022).
  5. **ClinicalTrials.gov

Disclaimer: This review is written from the perspective of film and genre critique, analyzing the work as a piece of media. It contains no explicitly prohibited content but discusses the themes inherent to the title.

1. The Science Behind MEYD‑873

Timeline (concise)

  1. Initial access — Day 0: Credential stuffing against company SSO combined with exploitation of an exposed internal-facing CI/CD runner; initial account compromised (service-account-level).
  2. Persistence — Day 1–3: Attacker deployed a lightweight backdoor inside a build artifact repository and scheduled an automated job to maintain access via short-lived tokens refreshed from the compromised service account.
  3. Discovery — Day 4–6: Rapid enumeration of cloud IAM roles, storage buckets, and telemetry endpoints; attacker harvested logging keys and metric-stream credentials.
  4. Lateral movement — Day 7–9: Using harvested telemetry credentials, the attacker access-mapped internal services, escalated privileges via a mis-scoped role, and created a new role with broad privileges.
  5. Data staging — Day 10–12: Sensitive telemetry and partial source code were staged to an encrypted S3-like bucket in a tenant-controlled account; some artifacts were exfiltrated through an innocuous-looking telemetry-forwarding API.
  6. Cleanup/covering tracks — Day 13–15: Logs were selectively deleted or redacted where the attacker had write access; synthetic telemetry events were injected to mask timing. Persistent access mechanisms remained active but dormant.
  7. Discovery & response — Day 16: Security team detected unusual metric-forwarding behavior and elevated egress to an external endpoint; incident response isolated affected roles and rotated keys.
Back to top button